Objective. This study aims to evaluate correlates of gait speed, a measure of disability, in older adults with advanced knee osteoarthritis (OA) and chronic pain. Conclusion. In a cross-sectional study of older adults with advanced knee OA and chronic pain, we found that age, arthritis function self-efficacy, and opioid use (but not dose) were significantly associated with decreased gait speed.
Introduction
A growing body of evidence demonstrates that osteoarthritis (OA) of the knee is one of the most highly prevalent conditions that causes chronic disability, especially in the older population [1] . Chronic pain conditions such as knee OA not only cause significant morbidity, but also are associated with increased costs to the health care system [2] .
In current clinical practice, the standard of care for knee OA is to focus treatment on pain reduction, with the presumption that improvements in function will follow. Although it is well supported by the literature that knee pain is associated with physical limitations, a clear linear association between these variables has not been demonstrated. Other moderating factors, such as comorbidity burden and psychological factors, may play key roles in determining the functional status of patients with painful knee OA [3] [4] [5] [6] [7] . For example, chronic health conditions such as diabetes are strongly linked to functional limitations in individuals with arthritis [3, 4] . Psychosocial factors such as depressive symptoms and low selfefficacy (e.g., symptom management and being physically active) are highly prevalent in patients with chronic pain conditions and are associated with low response rates to pain-specific interventions [4] [5] [6] [7] [8] . In addition, recent literature has raised alerts regarding opioid use for chronic pain, as misuse risk and adverse events, including functional disability and falls in the older adult, are common [7, 9] . Therefore, functional decline in patients with chronic OA pain is a complex process affected by several factors.
To date, no prior studies have evaluated correlates of a performance-based measure of physical function, such as gait speed, in subjects with advanced knee OA. This is important because recent literature has shown that gait speed is a valid and consistent predictor of lower extremity function and subsequent disability as well as mortality risk in older adults [10] [11] [12] [13] . Of note, it has been shown to be as reliable as the widely used Short Physical Performance Battery in detecting incident disability [10] . Because of its robustness and ease of implementation in the clinical setting, gait speed has come to be regarded as a "vital sign" for the older adult. Our novel analysis is based on this growing body of evidence that gait speed is highly predictive of frailty, disability risk, and mortality in the elderly [14] . The aim of this study is to identify correlates, independent of pain, that are associated with reduced gait speed in older adults with chronic pain and advanced knee OA.
Methods
The current analysis uses baseline, cross-sectional data collected from a randomized controlled clinical trial titled "Efficacy of Periosteal Stimulation and Exercise in Advanced Knee OA." Baseline data were collected between October 2009 and January 2012 in Pittsburgh, Pennsylvania. The data pooled include a total of 190 community-dwelling adults aged >50 with knee OA, as defined by American College of Rheumatology Classification criteria for knee pain for >25 of the past 30 days and osteophytes on knee X-ray. Participants were recruited from the Veterans Affairs Pittsburgh Healthcare System and the general community (16.2% were nonveterans) to include those with either bilateral or unilateral advanced knee OA, specifically Kellgren/Lawrence grade 3 or 4 [15] . Exclusion criteria for the study included the following: nonambulatory or severely impaired mobility (i.e., required the use of a walker); Folstein Mini-Mental State Examination score of <24; severe uncorrected visual or hearing impairment; knee pain due to factors other than OA (e.g., rheumatoid arthritis, gout, and metastatic cancer); large knee effusion interfering with function more than knee pain (by participant report); a history of corticosteroid or hyaluronic acid injection in the affected knee(s) during the preceding 3 months; acute or terminal illness; immune suppression (e.g., systemic steroids or other immune suppressants and HIV/AIDS); anticoagulation therapy (warfarin and low molecular weight heparin); and presence of pacemaker.
Socio-demographic characteristics including age and gender were ascertained by standard questions. A trained research coordinator used validated and reliable questionnaires to assess pain, health, and behavioral/ psychological parameters. Pain and function of the index joint was assessed using the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC) [16] . The WOMAC consists of 24 items divided into three subscales (pain, stiffness, and function) and has a 5-point Likert scale for each item. Each subscale has a score ranging from 0to 20 for pain, 0-8 for stiffness, and 0-86 for function. The final cumulative score is ascertained by summing items in each subscale. [17] . For the purpose of this analysis, we only considered the SF-36 global health subscale as other constructs (e.g., pain and function) were assessed by separate measures. Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale, which consists of 20 items rated on a 4-point Likert scale. Scores range from 0 to 60, with higher scores indicating more depressive symptoms, and a score of 16 or more indicating presence of depressive symptoms [18] . Coping strategies were assessed using the catastrophizing subscale of the Cognitive Strategies Questionnaire [19] . This subscale consists of six items that use a Likert scale from 0 to 6. Each subscale has a score range of 0-6; total score ranges from 0 to 36. Self-efficacy was assessed using the Arthritis Self-Efficacy Scale (ASES) with subscales for managing pain (pain self-efficacy [PSE]), physical function (function self-efficacy [FSE]), and controlling other symptoms (other self-efficacy [OSE]) [8, 20] . There are 20 total questions: five for PSE, nine for FSE, and six for OSE. Each question is scored on a 1-10 numeric rating scale; each subscale is scored separately and a mean score is used as the final score.
Comorbid conditions were assessed by a physician on the research team using the Cumulative Illness Rating Scale, a 14-item instrument [21] . Each item is scored from 0 to 4 (2 being moderate burden), and the instrument can be scored in one of two ways-either a total summary score is created, or the number of items with moderate or greater burden summed. We chose the latter method to represent comorbidity that is currently burdensome to participants [22] Medication use also was queried by a physician on the research team. Participants were asked to answer "yes" or "no" to taking any prescription or over-the-counter medications and were asked to list their medication names and dosages. All medications were categorized as analgesics (opioid or nonopioid) or nonanalgesics by the physician. Pain comorbidities were assessed by asking the participant to identify areas of pain other than the knee. For the purpose of analysis, body areas were divided into upper and lower body sections. Severity of lower body pain intensity was qualified in the following manner: none, little pain, moderate pain, quite bad, very bad pain, and pain is almost unbearable. Of note, participants were excluded if they reported pain frequency of every day or almost every day with pain intensity at any of the lower body sites ≥ their knee pain. A dichotomous variable was created for upper body pain (yes/no).
Gait speed was assessed using the standard 4-meter walk length and calculated in meters/second [23] . Participants were asked to walk at their usual pace, and the results were recorded in seconds. Immediately after completing the task, they were asked to repeat this performance task, and gait speed was calculated as the average of the two trials.
Statistical Analysis
We used descriptive statistics (mean, standard deviation, frequency, and percentage) to describe participant characteristics. First, we calculated Pearson correlation coefficients and conducted simple linear regression models to assess the associations of potential correlates with gait speed (without adjusting for knee pain). Correlation coefficients and regression coefficients were calculated for continuous variables, and only regression coefficients (differences between groups) were calculated for dichotomous/categorical variables. Then, we conducted the same analyses, adjusting for knee pain, to identify key correlates for inclusion in our multivariable regression model. In order to create a multivariable regression model, we conducted a series of hierarchical models. The first model included knee pain (per WOMAC), bilateral vs unilateral knee pain, and demographic factors; the second model added only those psychological/behavioral factors with univariate association significant at P < 0.2; the third model added comorbidities and opioid use if univariate associations were significant with P < 0.2. This full model provided the association of key correlates with gait speed, adjusting for knee pain.
For explanatory purposes, we assessed the correlation between opioid dose and gait speed using a scatter plot. We calculated the average daily dose of opioid analgesics by multiplying the number of dosage forms taken on a regular basis by medication strength. This average daily dose was then converted to oral morphine equivalents (OMEs) [24] . Subsequently, the average daily dose was converted to a standardized daily dose for opioids by dividing it by the minimum effective analgesic daily dose recommended for older adults (i.e., 15 mg/ day OME for opioids). Thus, a person taking 1.0 standardized opioid analgesic unit will have taken the minimum recommended effective analgesic dose for older adults for one agent [24] . SAS ® version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all statistical analyses.
Results
The vast majority of participants were male (84.7%) with a mean (standard deviation) age of 66.6 (9.4) years (Table 1) In the univariate analysis, knee pain (per WOMAC), age, depressive symptoms, catastrophizing, number of comorbidities, and opioid use were negatively associated with gait speed (all P values <0.05; Table 2 ). The unadjusted absolute difference in gait speed between those using any opioid use and those either using no pain medications or only nonopioid use was 0.12 m/s (Table 2) . Global health, ASES function, and ASES other were positively associated with gait speed. After controlling for knee pain (per WOMAC), age, ASES function, comorbidity, and opioid use remained significant (Table 2 ).
In the fully adjusted multivariable model, controlling for knee pain, older age (P < 0.0001), lower ASES function (P < 0.0001), and opiod use (P = 0.003) were associated with worse gait speed (Table 3) . After adjusting for important correlates, the difference in mean gait speed between these two groups was statistically significant (regression coefficient = −0.08; P = 0.009), indicating a slower gait speed in those using any opioid (Table 3) . For explanatory purposes, we assessed the correlation between opioid dose and gait speed to determine if the association with opioid use showed a dose response relationship. The correlation between opioid dose and gait speed (among opioid users) was not statistically significant (r = 0.04; P = 0.81; data not shown).
Discussion
In a cross-sectional study of older adults with advanced knee OA and chronic pain, we found that age, arthritis function self-efficacy, and opioid use were significantly associated with decreased gait speed. These findings are consistent with previous research and also advance the field by reporting new correlates of physical function in patients with advanced knee OA-i.e., self-efficacy and opioid use. In addition, our study is unique in that it characterizes gait speed in patients with severe, advanced knee OA.
Previous research has examined gait speed as a measure of physical function in patients with knee OA. For example, White et al. characterized trajectories of gait speed decline using data from the Osteoarthritis Initiative cohort study [25] . Of the 4,179 participants studied, those with symptomatic knee OA had an almost ninefold risk of a fast decline trajectory of gait speed compared with people with neither pain nor radiographic knee OA. This study was able to control for important potential confounders (i.e., age, sex, race, education, comorbidity, depressive symptoms, BMI, physical activity, knee strength, and knee pain intensity); however, they did not collect analgesic information and were, thus, unable to examine the impact of opioids on physical function. In addition, Sowers et al. studied performance-based physical functioning in black and white middle-aged women in order to examine associations with important variables [26] . They found the following variables to be significantly correlated with gait speed (mean gait speed: 1.45 m/s): increasing age, increasing fat mass, knee joint pain, and reduced quadriceps strengths. As with the study by White et al., analgesic use was not collected. As expected, we also found increased age to be associated with decreased gait speed. It is important to note the differences between our study and these two prior studies. We included participants with Kellgren/Lawrence grade 3 or 4 knee OA, where these prior studies included Kellgren/Lawrence grade ≥2. This might explain why the average gait speed detected in the current study was relatively low at 0.8 m/s.
Most importantly, to the best of our knowledge, this is the first study to collect detailed information on opioid analgesic use in order to examine associations with gait speed.
It is worth highlighting that we found opioid users had slower gait speed than opioid nonusers. Moreover, the absolute difference in average gait speed between these two groups at baseline was 0.12 m/s, and the adjusted difference was 0.08 m/s, with opioid users performing slower. Previous research has shown that a change in gait speed as small as 0.05 m/s is meaningful, and a change of 0.1 m/s is substantial [27] [28] [29] Thus, we detected a clinically meaningful difference in average gait speed between opioid users and opioid nonusers, independent of other important confounders. Furthermore, we did not uncover a dose-response effect among opioid users. There may be several explanations for these findings. Opioids are centrally acting analgesics, and the sensitivity to their positive and negative effects are determined by a variety of complex interacting genetic and nongenetic factors that have yet to be well delineated [30] . A large body of gerontology literature has highlighted the link between brain function and gait speed [31, 32] ; thus, the fact that opioid users had a slower gait speed than nonusers is not surprising. The lack of a dose-response relationship may relate to the relatively small number of opioid users in our study, making it difficult to robustly examine associations across the dosing spectrum. In addition, opioid use may simply be a marker for an important confounder that we were unable to measure in the current study.
Finally, self-efficacy has been shown to be an important predictor of outcomes in numerous health care domains, ranging from behavioral modification (such as smoking cessation) to pain management [33] [34] [35] [36] . More specifically, we found arthritis self-efficacy (e.g., self-management, pain, and physical activity) to be associated with gait speed. Little is known about the association of selfefficacy and gait speed in patients with advanced knee OA. One study by DePew et al. found self-efficacy to be a predictor of 4-meter gait speed in patients with severe chronic lung disease [37] . However, this study used a nonvalidated questionnaire to measure self-efficacy. Thus, future work is needed in patients specifically with knee OA using a validated instrument such as the ASES to evaluate the role of self-efficacy in physical function. In addition, clinicians should consider assessing patients for selfefficacy in order to identify potential areas for intervention to improve outcomes.
Although our study had a number of strengths, its limitations deserve mention. First, this was a cross-sectional study, so we were unable to identify changes in gait speed over time. In additional, temporal relationships or a causal link between the variables cannot be determined. Second, confounding by indication is a concern in any observational study assessing medication exposure. However, to address this potential bias, we controlled for knee pain (and pain comorbidity) as well as a number of important potential confounders that may have affected the outcome. Despite this, there may have been unmeasured confounders that we were not able to measure. Third, there is a wide variety of modalities that can be used for the treatment of knee OA, such as physical therapy. However, we were not able to include information on participation in and compliance with such treatments given the cross-sectional nature of this analysis. Fourth, our sample size was relatively small, which may have limited our ability to detect associations with some other key variables such as depressive symptoms. In addition, a minority of participants used opioids, possibly limiting our ability to robustly examine opioid dose-response relationships with gait speed. Finally, our study sample was primarily white males, so our results may not apply to other populations.
Conclusion
This is the first study to evaluate biopsychosocial predictors of gait speed, a robust predictor of future disability, in older adults with advanced knee OA-associated chronic pain. We investigated correlates that have been previously implicated to play a role in the deterioration of function in the older adult in general and in those with advanced knee OA in particular. We found robust independent associations of age, self-efficacy, and opioid use with gait speed.
